Lord, Abbett & Co
TERN

Lord, Abbett & Co’s Terns Pharmaceuticals TERN Stock Holding History

Lord, Abbett & Co’s Portfolio TERN Stock Details TERN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-2,812,938
Closed -$148M – 629
2026
Q1 		$148M Buy
2,812,938
+100,539
+4% +$4.13M 0.48% 53
2025
Q4 		$110M Buy
+2,712,399
New +$62.7M 0.34% 80

Other funds holding TERN

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Lord, Abbett & Co's TERN Position: Q2 2026 in Review

Lord, Abbett & Co sold out of Terns Pharmaceuticals (TERN) in Q2 2026, closing a stake of 2,812,938 shares — an estimated $148M sold.

Lord, Abbett & Co first reported a position in TERN in Q4 2025 and held it in 2 quarters. The position peaked at $148M in Q1 2026. 1 fund tracked by Wall St. Rank holds TERN as of Q2 2026.

  • Lord, Abbett & Co reported no remaining Terns Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Lord, Abbett & Co sold 2,812,938 Terns Pharmaceuticals shares in Q2 2026, an estimated $148M.
  • Lord, Abbett & Co first reported a position in Terns Pharmaceuticals in Q4 2025 and held it in 2 quarters.
  • Lord, Abbett & Co's Terns Pharmaceuticals position peaked at $148M in Q1 2026.
  • 1 fund tracked by Wall St. Rank held Terns Pharmaceuticals as of Q2 2026.

Based on Lord, Abbett & Co's 13F filing for Q2 2026, filed 14 Aug 2026.